Stevanato Group S.p.A. (STVN)
After hours:
| Previous close | 27.52 |
| Open | 27.98 |
| Bid | 10.99 x 800 |
| Ask | 27.53 x 1200 |
| Day's range | 27.35 - 28.17 |
| 52-week range | 23.00 - 36.30 |
| Volume | |
| Avg. volume | 380,822 |
| Market cap | 7.512B |
| Beta (5Y monthly) | 0.70 |
| PE ratio (TTM) | 46.68 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.06 (0.22%) |
| Ex-dividend date | 07 June 2023 |
| 1y target est | N/A |
- Business Wire
Stevanato Group to Report First Quarter 2024 Financial Results on May 9, 2024
PIOMBINO DESE, Italy, April 25, 2024--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2024 on Thursday, May 9, 2024, at 6:30 a.m. (ET).
- Business Wire
Stevanato Group appoints Ugo Gay as Chief Operations Officer
PIOMBINO DESE, Italy, April 04, 2024--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, today announced the appointment of Ugo Gay as its new Chief Operations Officer (COO).
- Business Wire
Stevanato Group Announces Closing of Upsized Public Offering of Ordinary Shares and Exercise in Full of the Underwriters’ Option to Purchase Additional Ordinary Shares
PIOMBINO DESE, Italy, March 26, 2024--Stevanato Group S.p.A. (NYSE: STVN) ("Stevanato Group," or the "Company"), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the closing of its previously announced upsized underwritten public offering of an aggregate of 14,605,000 of its ordinary shares, which includes the full exercise of the underwriters’ option to purchase 1,905,000 addi
